A Phase Ib, Randomized, Open-label, Multi-center Study to Evaluate the Preliminary Efficacy and Safety of Furmonertinib Mesilate in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation
Latest Information Update: 19 Aug 2026
At a glance
- Drugs Firmonertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FAVOUR
- Sponsors Allist Pharmaceuticals
Most Recent Events
- 14 Aug 2026 Status changed from active, no longer recruiting to completed.
- 19 Nov 2025 Planned End Date changed from 31 Aug 2025 to 28 Feb 2026.
- 03 Apr 2025 Planned End Date changed from 1 Dec 2023 to 31 Aug 2025.